A novel approach to assess Lung Health

Functional Respiratory Imaging (FRI) is a imaging technology which enhances drug development and patient care by providing patient-specific parameters

A novel approach to assess Lung Health

Functional Respiratory Imaging (FRI) is a imaging technology which enhances drug development and patient care by providing patient-specific parameters

Patient-specific parameters

  • 3D visualization and quantification of patient’s airway and lung geometry on a regional, often lobar, level
  • Deposition characteristics of inhaled compounds

Patient-specific parameters

  • 3D visualization and quantification of patient’s airway and lung geometry on a regional, often lobar, level
  • Deposition characteristics of inhaled compounds

FRI benefits

Use in Clinical Trials

FRI reduces the cost and time required for screening most promising new respiratory drugs in early clinical phase

Use in Clinical Practice

FRI is sensitive and identifies more quickly inefficient therapies, improving patient care

FRI benefits

Use in Clinical Trials

FRI reduces the cost and time required for screening most promising new respiratory drugs in early clinical phase

Use in Clinical Practice

FRI is sensitive and identifies more quickly inefficient therapies, improving patient care

FLUIDDA’s technique and insights to the subject were outstanding. We were delighted with the science and collaboration we had with FLUIDDA.

Mark Milton – Edwards Global Dir. Respiratory, TEVA

FLUIDDA’s technology is an important tool which helps bridge data from in vitro and in vivo studies.

Dr. Paul M. Dorinsky – Head Global Respiratory Clinical Development, Cipla

FLUIDDA’s technique and insights to the subject were outstanding. We were delighted with the science and collaboration we had with FLUIDDA.

Mark Milton – Edwards Global Dir. Respiratory, TEVA

FLUIDDA’s technology is an important tool which helps bridge data from in vitro and in vivo studies.

Dr. Paul M. Dorinsky – Head Global Respiratory Clinical Development, Cipla

For the next 5 days the FLUIDDA team will be present at the annual European Respiratory Society conference in Paris.
Read More
We are happy to announce that a few days ago the positive results of AstraZeneca’s Bevespi (LABA/LAMA), compared to placebo
Read More
A thorough understanding of a pharmaceutical company’s target disease is imperative when it wants to successfully develop and market its
Read More
We’ve said it before: the respiratory field is the most expensive one in the pharmaceutical world. The low sensitivity of
Read More